Compare Essex Property Trust, Inc. (ESS) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Essex Property Trust, Inc. vs Neurocrine Biosciences Inc — how do they compare? Essex Property Trust, Inc. trades at $269.13 (market cap $17.23B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B). The key difference: Essex Property Trust, Inc. is the larger of the two by market cap, and Essex Property Trust, Inc. pays a 3.86% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Essex Property Trust, Inc. for 111 Days and Neurocrine Biosciences Inc for 23 Days on average.
| ESS | NBIX | |
|---|---|---|
Market Cap | $17.23B | $14.60B |
Volume | 346,109 | 1,075,694 |
Sector | Real Estate | Health |
52-Week High | $298.33 | $185.50 |
52-Week Low | $239.61 | $123.10 |
Typical Hold Time | 111 Days | 23 Days |
Enterprise Value | $23.82B | $14.61B |
Dividend Yield | 3.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ESS trades at $268.05, down 1.63% with bearish technical signals. The company reported mixed Q2 2026 results, beating FFO estimates but missing EPS expectations. Strong operational performance and litigation resolution provide fundamental support, though high valuation ratios and debt levels present concerns. Recent institutional buying and a $2.59 dividend declaration highlight investor confidence.
Outlook remains cautiously optimistic with a $303.41 consensus price target offering 13% upside. Key risks include earnings volatility, high leverage, and regional economic exposure. The stock presents a balanced opportunity for income-focused investors seeking quality REIT exposure with disciplined risk management.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
